Vimarsana
Biggest News Aggregation in the World

Highest Dose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Highest Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Highest Dose Today - Breaking & Trending Today

Novel Toothpaste May Cut Peanut Allergy Risk for Adults - Vimarsana News

Novel Toothpaste May Cut Peanut Allergy Risk for Adults

A phase 1 randomized, controlled trial tested the safety of a toothpaste that was specially formulated to be used as oral immunotherapy by adults with peanut allergy.

Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy - Vimarsana News

Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy

- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging... | April 26, 2023

Alnylam Pharmaceuticals, Inc.: Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy - Vimarsana News

Alnylam Pharmaceuticals, Inc.: Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy

Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPa and sAPPß in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date Encouraging Clinical Safety and

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily - Vimarsana News

Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily

Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks1At the Highest Dose of TAK-279, 46% of Patients Achieved PASI 90 and 33% Achieved PASI 100 at 12 Weeks, Indicating a Near-Total or Total Clearan...

Covid 19 vaccination: 1 दिन में सर्वाधिक खुराक लगाने का रिकॉर्ड, इतिहास में दर्ज होगा सोमवार का दिन | covid 19 - Vimarsana News

Covid 19 vaccination: 1 दिन में सर्वाधिक खुराक लगाने का रिकॉर्ड, इतिहास में दर्ज होगा सोमवार का दिन | covid 19

नई दिल्ली। भारत ने 16 अगस्त को कोविड-19 टीके की सर्वाधिक 88.13 लाख से अधिक खुराक लगाई। केंद्रीय स्वास्थ्य मंत्रालय ने मंगलवार को यह जानकारी दी। केंद्रीय स्वास्थ्य मंत्री मनसुख मांडविया ने ट्वीट किया कि भारत ने 1 दिन में सबसे अधिक कोविड-...